Should clinical  studies guide clinical practice?

Christiane Hartog

doi:10.4414/smw.2012.13657

Viewpoint

Vol. 142 No. 3132 (2012)

Should clinical studies guide clinical practice?

Christiane Hartog

DOI: https://doi.org/10.4414/smw.2012.13657
Cite this as:: Swiss Med Wkly. 2012;142:w13657
Published: 29.07.2012

References

Singer M, Glynne P. Treating critical illness: the importance of first doing no harm. PLoS Med. 2005;2(6):p.e167.
Sackett DL, et al. Evidence based medicine: what it is and what it isn't. BMJ. 1996;312(7023):p.71–2.
Nitsch E. [Volume replacement with artifical colloids]. Anasthesiol Intensivmed Notfallmed Schmerzther. 1998.33(4):255–60.
Avorn J. Learning about the safety of drugs--a half-century of evolution. N Engl J Med. 2011;365(23):2151–3.
Maio G. [On the history of the Contergan (thalidomide) catastrophe in the light of drug legislation]. Dtsch Med Wochenschr. 2001;126(42):1183–6.
Thomas-Rueddel DO, et al. Safety of gelatin for volume resuscitation-a systematic review and meta-analysis. Intensive Care Med. [Epub ahead of print], 2012.
Hartog CS, Kohl M, Reinhart K. A systematic review of third-generation hydroxyethyl starch (HES 130/0.4) in resuscitation: safety not adequately addressed. Anesth Analg. 2011.112(3):635–45.
Perel P, Roberts I. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev. 2011.3:CD000567.
Bunn F, Trivedi D, Ashraf S. Colloid solutions for fluid resuscitation. Cochrane Database Syst Rev. 2011.3:CD001319.
Human albumin administration in critically ill patients: systematic review of randomised controlled trials. Cochrane Injuries Group Albumin Reviewers. BMJ. 1998;317(7153):235–40.
Finfer S, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004;350(22):2247–56.
Puyana JC. Resuscitation of hypovolemic shock. In: M. Fink, et al. Editors. Textbook of critical care. Elsevier Saunders: Philadelphia. 2005;1939–40.
Wiedermann CJ, Joannidis M. Mortality after hydroxyethyl starch 130/0.4 infusion: an updated meta-analysis of randomized trials. Swiss Med Wkly. 2012;142:w13656.
McGauran N, et al. Reporting bias in medical research – a narrative review. Trials. 2012;11:37.
Jefferson T, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Cochrane Database Syst Rev. 2012;(2):CD001265.
James MF, et al. Resuscitation with hydroxyethyl starch improves renal function and lactate clearance in penetrating trauma in a randomized controlled study: the FIRST trial (Fluids in Resuscitation of Severe Trauma). Br J Anaesth. 2011;107(5):693–702.
James MFM, et al. Re:Hydroxy ethyl starch in patients with trauma, author's reply. Br J Anaesth. 2011;DOI: http://bja.oxfordjournals.org/content/107/5/693.long/reply#brjana_el_7942.
Guidet B, et al. Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 versus 0.9% NaCl fluid replacement in patients with severe sepsis: The CRYSTMAS study. Critical Care. 2012;16(3):R94.
Package insert Voluven. Vaccines, blood & biologics 2012 [cited 2012 7th May]. Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/.
Lexchin J, et al. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003;326(7400):1167–70.
Perner A, et al. Hydroxyethyl Starch 130/0.4 versus Ringer's acetate in severe sepsis. N Engl J Med. 2012;367(2):124–34.
Myburgh J. et al. Statistical analysis plan for the Crystalloid Versus Hydroxyethyl Starch Trial (CHEST). Critical care and resuscitation. Journal of the Australasian Academy of Critical Care Medicine. 2012;14(1):44–52.
Schortgen F. et al. The risk associated with hyperoncotic colloids in patients with shock. Intensive Care Med. 2008;34(12):2157–68.
Liu FC, et al. Hydroxyethyl starch interferes with human blood ex vivo coagulation, platelet function and sedimentation. Acta Anaesthesiol Taiwan. 2009;47(2):71–8.
Basora M, et al. [Perioperative colloid administration: a survey of Spanish anesthesiologists' attitudes]. Rev Esp Anestesiol Reanim. 2007.54(3):162–8.
Preferences for colloid use in Scandinavian intensive care units. Acta Anaesthesiol Scand. 2008.52(6):p.750–8.
Hartog CS. et al. Systematic analysis of hydroxyethyl starch (HES) reviews: proliferation of low-quality reviews overwhelms the results of well-performed meta-analyses. Intensive Care Med. 2012;38(8):1258–71.

How to Cite

1.

Hartog C. Should clinical studies guide clinical practice?. Swiss Med Wkly [Internet]. 2012 Jul. 29 [cited 2024 Apr. 16];142(3132):w13657. Available from: https://smw.ch/index.php/smw/article/view/1548

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

[1] Singer M, Glynne P. Treating critical illness: the importance of first doing no harm. PLoS Med. 2005;2(6):p.e167.

[2] Sackett DL, et al. Evidence based medicine: what it is and what it isn't. BMJ. 1996;312(7023):p.71–2.

[3] Nitsch E. [Volume replacement with artifical colloids]. Anasthesiol Intensivmed Notfallmed Schmerzther. 1998.33(4):255–60.

[4] Avorn J. Learning about the safety of drugs--a half-century of evolution. N Engl J Med. 2011;365(23):2151–3.

[5] Maio G. [On the history of the Contergan (thalidomide) catastrophe in the light of drug legislation]. Dtsch Med Wochenschr. 2001;126(42):1183–6.

[6] Thomas-Rueddel DO, et al. Safety of gelatin for volume resuscitation-a systematic review and meta-analysis. Intensive Care Med. [Epub ahead of print], 2012.

[7] Hartog CS, Kohl M, Reinhart K. A systematic review of third-generation hydroxyethyl starch (HES 130/0.4) in resuscitation: safety not adequately addressed. Anesth Analg. 2011.112(3):635–45.

[8] Perel P, Roberts I. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev. 2011.3:CD000567.

[9] Bunn F, Trivedi D, Ashraf S. Colloid solutions for fluid resuscitation. Cochrane Database Syst Rev. 2011.3:CD001319.

[10] Human albumin administration in critically ill patients: systematic review of randomised controlled trials. Cochrane Injuries Group Albumin Reviewers. BMJ. 1998;317(7153):235–40.

[11] Finfer S, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004;350(22):2247–56.

[12] Puyana JC. Resuscitation of hypovolemic shock. In: M. Fink, et al. Editors. Textbook of critical care. Elsevier Saunders: Philadelphia. 2005;1939–40.

[13] Wiedermann CJ, Joannidis M. Mortality after hydroxyethyl starch 130/0.4 infusion: an updated meta-analysis of randomized trials. Swiss Med Wkly. 2012;142:w13656.

[14] McGauran N, et al. Reporting bias in medical research – a narrative review. Trials. 2012;11:37.

[15] Jefferson T, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Cochrane Database Syst Rev. 2012;(2):CD001265.

[16] James MF, et al. Resuscitation with hydroxyethyl starch improves renal function and lactate clearance in penetrating trauma in a randomized controlled study: the FIRST trial (Fluids in Resuscitation of Severe Trauma). Br J Anaesth. 2011;107(5):693–702.

[17] James MFM, et al. Re:Hydroxy ethyl starch in patients with trauma, author's reply. Br J Anaesth. 2011;DOI: http://bja.oxfordjournals.org/content/107/5/693.long/reply#brjana_el_7942.

[18] Guidet B, et al. Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 versus 0.9% NaCl fluid replacement in patients with severe sepsis: The CRYSTMAS study. Critical Care. 2012;16(3):R94.

[19] Package insert Voluven. Vaccines, blood & biologics 2012 [cited 2012 7th May]. Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/.

[20] Lexchin J, et al. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003;326(7400):1167–70.

[21] Perner A, et al. Hydroxyethyl Starch 130/0.4 versus Ringer's acetate in severe sepsis. N Engl J Med. 2012;367(2):124–34.

[22] Myburgh J. et al. Statistical analysis plan for the Crystalloid Versus Hydroxyethyl Starch Trial (CHEST). Critical care and resuscitation. Journal of the Australasian Academy of Critical Care Medicine. 2012;14(1):44–52.

[23] Schortgen F. et al. The risk associated with hyperoncotic colloids in patients with shock. Intensive Care Med. 2008;34(12):2157–68.

[24] Liu FC, et al. Hydroxyethyl starch interferes with human blood ex vivo coagulation, platelet function and sedimentation. Acta Anaesthesiol Taiwan. 2009;47(2):71–8.

[25] Basora M, et al. [Perioperative colloid administration: a survey of Spanish anesthesiologists' attitudes]. Rev Esp Anestesiol Reanim. 2007.54(3):162–8.

[26] Preferences for colloid use in Scandinavian intensive care units. Acta Anaesthesiol Scand. 2008.52(6):p.750–8.

[27] Hartog CS. et al. Systematic analysis of hydroxyethyl starch (HES) reviews: proliferation of low-quality reviews overwhelms the results of well-performed meta-analyses. Intensive Care Med. 2012;38(8):1258–71.